PEDIATRIC ONCOLOGY GROUP

这项建议是要求支持参加联合国 儿科肿瘤组（POG）。 这项合作研究致力于 急性白血病化疗方法的研究， 其他儿童肿瘤性疾病。 显著缓解， 延长了生存期， 在临床药理学上。 然而，这些研究的真实的目的是 通过治疗根除肿瘤疾病。 研究正在 旨在反映对肿瘤的攻击强度不断增加 cell. 合作小组技术允许迅速评价系列 合理大小的有希望的化疗药物。 这些线索还是新的 方法往往是由小组自己的工作结果提出的， 临床肿瘤学 因此，一个完整的协议往往建议新的 在新协议中探索的途径。 此外，协议 旨在利用在以下方面取得的最大临床或概念进展 实验动物和/或临床初步研究。 司 儿科血液学-肿瘤学 加州大学圣地亚哥分校（UCSD）有10年的历史， 参与癌症和白血病组B的合作组研究 在1980年加入儿科肿瘤学小组之前。 期间 在过去的18个月里，我们已经进入了30个方案的138名患者：63 治疗方案中的患者和登记研究中的45例患者，或 非治疗性辅助研究。 此外，我们还参与了 集团委员会工作和新集团协议研究的设计。 我们计划 继续积极参与POG活动的各个阶段。

This proposal represents a request to support participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic approaches to acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests the new avenues to be explored in new protocols. In addition, protocols are designed to exploit maximal clinical or conceptual advances made in experimental animals and/or clinical pilot studies. The Division of Pediatric Hematology-Oncology in the Department of Pediatrics at the University of California, San Diego (UCSD) has a 10 year history of involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with the Pediatric Oncology Group in 1980. During the past 18 months, we have entered 138 patients on 30 protocols: 63 patients on treatment protocols and 45 patients on registries or non-therapeutic ancillary studies. In addition, we have been involved in Group committee work and the design of new Group protocol studies. We plan to continue our active participation in all phases of POG activities.